In the BioHarmony Drug Report Database

"Preview" Icon

Selexipag

Uptravi (selexipag) is a small molecule pharmaceutical. Selexipag was first approved as Uptravi on 2015-12-21. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. It is known to target prostacyclin receptor. Uptravi’s patents are valid until 2036-12-01 (FDA).

 

Trade Name

 

Uptravi
 

Common Name

 

selexipag
 

ChEMBL ID

 

CHEMBL238804
 

Indication

 

pulmonary hypertension
 

Drug Class

 

Image (chem structure or protein)

Selexipag structure rendering